PrognosDx, Flagship Partner to Provide Histone Testing Services

Epigenetics company PrognosDx and digital pathology firm Flagship will offer laboratory-based testing services initially to therapeutic oncology programs at pharmaceutical firms.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.